8-K: Enliven Therapeutics: Positive Phase 1 Data for CML Drug ELVN-001

Enliven Therapeutics announced updated positive Phase 1 data for its CML drug ELVN-001, showing encouraging efficacy and a favorable safety profile, and confirmed alignment with the FDA on Phase 3 trial design.

Summary

• Enliven Therapeutics presented updated positive data from its Phase 1 ENABLE clinical trial for ELVN-001, a treatment for chronic myeloid leukemia (CML).
• The data, as of March 10, 2026, included 161 patients, with 76% remaining on study and a median treatment duration of 35 weeks.
• A significant portion of patients (70%) were heavily pretreated, having received three or more prior unique tyrosine kinase inhibitors (TKIs), and 23% had received five or more.
• In the Phase 1b cohort, 69 patients were evaluable for major molecular response (MMR) by 24 weeks, with an overall MMR rate of 54%.
• The 80 mg once daily (QD) Phase 1b cohort showed a 61% overall MMR rate and 48% MMR achievement by 24 weeks.
• Deep Molecular Response (DMR) was achieved by 22% of patients in the overall Phase 1b and 30% in the 80 mg QD cohort by 24 weeks.
• ELVN-001 demonstrated a generally well-tolerated safety profile, with 6% of patients discontinuing due to adverse events.
• Grade 3 treatment-emergent adverse events (TEAEs) were reported in 34% of patients overall, and 24% in the 80 mg QD cohort.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with strong clinical data and regulatory alignment, indicating good progress in the drug development pipeline.

Positives

• Updated positive data from the Phase 1 ENABLE clinical trial for ELVN-001 in CML patients.
• High patient retention rate: 76% of patients remain on study with a median treatment duration of 35 weeks.
• Encouraging efficacy: 54% overall MMR rate in the Phase 1b cohort and 61% in the 80 mg QD cohort by 24 weeks.
• Deep Molecular Response (DMR) achieved by 22% (overall Phase 1b) and 30% (80 mg QD cohort) by 24 weeks.
• Favorable safety and tolerability profile, consistent with high selectivity.
• 80 mg QD selected as the recommended dose for the Phase 3 ENABLE-2 trial.
• Alignment with the FDA on the Phase 3 ENABLE-2 trial design, including the patient population (previously treated with one or more TKIs).

Negatives

• Grade 3 TEAEs reported in 34% of patients overall, with thrombocytopenia, neutropenia, and lipase elevation being the most common.
• Response rates were higher in less heavily pretreated patients, suggesting potential for reduced efficacy in more advanced disease stages.
• The company has not performed head-to-head trials, limiting direct comparisons to existing therapies.

Risks

• Potential for interim, topline, and preliminary results to materially change as more data becomes available.
• Results from future clinical trials may differ from earlier trials.
• ELVN-001 may fail to demonstrate sufficient safety, efficacy, tolerability, durability, or therapeutic benefit in future trials.
• Risks associated with unexpected adverse events, dose reductions, or discontinuations during clinical trials.
• Delays or difficulties in patient recruitment, enrollment, or maintenance in clinical trials.
• Regulatory authorities may disagree with trial design, dose selection, endpoints, or data interpretation, potentially requiring additional studies.
• Lack of reliability of cross-trial comparisons due to differences in trial design and patient populations.
• Competition from other therapies and potential market opportunity impacts.

Future Outlook

The company has aligned with the FDA on the 80 mg QD dose and the patient population for the Phase 3 ENABLE-2 trial, which is expected to enroll patients previously treated with one or more TKIs. The ENABLE-2 trial is anticipated to initiate in the second half of 2026. Further discussions with the FDA are planned, including an End-of-Phase 2 meeting in the third quarter of 2026, to finalize additional Phase 3 trial design details.

Management Comments

• "The updated data from the ENABLE trial are very promising and encouraging. The trial demonstrated meaningful responses across lines of therapy in heavily pretreated patients, including responses in patients who had shown a lack of efficacy to the most effective approved therapies. Further, ELVN-001 demonstrated a favorable safety and tolerability profile, reflecting its high selectivity. I look forward to the initiation of the planned Phase 3 ENABLE-2 trial, which could establish ELVN-001 as an important new treatment option for patients with previously treated CML." - Dennis Kim, M.D., Professor of Medicine, Princess Margaret Cancer Centre.
• "These promising results continue to showcase the consistency of ELVN-001s overall profile and reinforce its potential to be a best-in-class ATP-competitive inhibitor with differentiated activity relative to allosteric inhibitors. In these data, we observed higher response rates in patients treated in earlier lines of therapy, and comparable response rates regardless of prior asciminib exposure. We are also thrilled by the outcome of our recent End-of- Phase 1 meeting with the FDA, where we reached alignment on the 80 mg once daily dose and the inclusion of patients who have received at least one prior TKI in the planned ENABLE-2 Phase 3 trial. This is an important milestone as we advance towards initiating ENABLE-2 later this year." - Helen Collins, M.D., Chief Medical Officer of Enliven.

Industry Context

StockSavvy.ai notes that Enliven Therapeutics' announcement positions ELVN-001 as a potentially best-in-class ATP-competitive inhibitor for CML, aiming to differentiate itself from existing allosteric inhibitors. The alignment with the FDA on Phase 3 trial design is a significant step, indicating regulatory confidence in the drug's development path.

Comparison to Industry Standards

• The filing does not provide direct head-to-head comparisons with specific competitor products or industry benchmarks due to the absence of head-to-head trials.
• Data presented are derived from different clinical trials at different points in time with varying designs and patient populations, making direct cross-trial comparisons unreliable.

Stakeholder Impact

• Shareholders: Positive news regarding clinical trial progress and FDA alignment could lead to increased investor confidence and potentially impact share price.
• Patients: Potential for a new, effective treatment option for CML patients, especially those who are heavily pretreated or have resistance to existing therapies.
• Healthcare Providers: Provides new data and a potential new therapeutic option to consider for CML treatment.

Next Steps

• Finalize additional Phase 3 trial design details following further discussions with the FDA.
• Initiate the Phase 3 ENABLE-2 trial in the second half of 2026.
• Present additional clinical data and presentation materials as they become available.
• Continue clinical development of ELVN-001.

Key Dates

Recommendation

The positive Phase 1 data and FDA alignment are encouraging, but the drug is still in early-stage development. Further clinical trial results and regulatory approvals are needed before a stronger recommendation can be made. The current 'hold' reflects cautious optimism pending more definitive data.

Keywords

Enliven Therapeutics, ELVN-001, Chronic Myeloid Leukemia, CML, Phase 1 Clinical Trial, ENABLE Trial, FDA, Tyrosine Kinase Inhibitors